Celltrion And Rani Partner For Oral Adalimumab
Deal For Humira Rival Builds On Collaboration For Oral Version Of Ustekinumab
Celltrion has doubled down on its alliance with Rani Therapeutics for oral pill versions of biosimilars by adding adalimumab to an existing collaboration covering ustekinumab.
You may also be interested in...
As biosimilars to Stelara (ustekinumab) continue to advance in global markets, Rani Therapeutics has made progress for its proposed RT-111 orally administered ustekinumab biosimilar.
Having previously an agreement with BioFactura to assess the company’s proposed ustekinumab biosimilar with its RaniPill oral drug delivery technology, Rani has now unveiled a deal with Korean major Celltrion for use of its CT-P43 Stelara biosimilar candidate.
The advent of US biosimilar competition to Humira in 2023 represents the largest ever loss-of-exclusivity opportunity for the off-patent industry, with the first adalimumab rival expected to hit the US market at the end of this month. But with a host of other biosimilars expected to launch throughout the year, how will competition play out in the long term?